TEE
BLFS icon

Tibra Equities Europe’s BioLife Solutions BLFS Stock Holding History

Tibra Equities Europe’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-22,054
Closed -$395K – 273
2019
Q1 		$395K Buy
+22,054
New +$351K 0.04% 290

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Tibra Equities Europe's BLFS Position: Q2 2019 in Review

Tibra Equities Europe sold out of BioLife Solutions (BLFS) in Q2 2019, closing a stake of 22,054 shares — an estimated $395K sold.

Tibra Equities Europe first reported a position in BLFS in Q1 2019 and held it in 1 quarter. The position peaked at $395K in Q1 2019. 73 funds tracked by Wall St. Rank hold BLFS as of Q2 2019.

  • Tibra Equities Europe reported no remaining BioLife Solutions position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 22,054 BioLife Solutions shares in Q2 2019, an estimated $395K.
  • Tibra Equities Europe first reported a position in BioLife Solutions in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's BioLife Solutions position peaked at $395K in Q1 2019.
  • 73 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.